Continuing the unprecedented wave of consolidation seen in the OTC pharmaceutical sector thus far in 2014, Perrigo has agreed to acquire Belgium-based Omega Pharma for €3.6 B (US$4.5 B), including the assumption of €1.1 B (US$1.4 B) in debt. The deal will accelerate Perrigo’s international growth strategy, diversifying its revenue streams and giving it access to an established commercial infrastructure in Europe.